Skip to main content
AZN logo

AstraZeneca PLC (AZN) Stock: Price, Forecast & Analyst Target

AstraZeneca PLC (AZN) — MoonshotScore 85/100 (Exceptional band), calculated Nov 18, 2026. Price $178.76 (-1.93%), as of the Nov 18, 2026 trading session; market cap $277B. Expected results Feb 9, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 33.98× (cash as of Sep 30, 2026) · expected results Feb 9, 2027

$178.76 −$3.51 (-1.93%) Market Cap $277B

AstraZeneca PLC · AZN · NYSE · Healthcare · Drug Manufacturers - General

Research dated 2026-09-12: AstraZeneca discovers, develops, manufactures and commercializes prescription medicines, with oncology, cardiovascular, renal, metabolic and rare-disease franchises carrying the business today. Its case depends on whether expanding medicine sales can keep outrunning heavy pipeline spending while preserving cash generation and containing leverage.

Price as of Nov 18, 2026

Key Statistics

85 of 100

MoonshotScore v2 · AstraZeneca (AZN)

Exceptional
Business Quality Elite (91)
Financial Safety Okay (59)
Valuation Full (49)
Growth Durability Compounding (84)
Momentum Surging (80)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality and durable growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.

  • EPS beat 6 of the last 8 reports
  • Altman Z 3.59 · Piotroski F 7
  • ROE 22.3% · ROA 9.3% · current ratio 1.01 · earnings yield 3.9% · free-cash-flow yield 3.2%

Helping: business quality, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for AZN (52 recorded, newest six shown)
RecordedScoreBand
87Exceptional
88Exceptional
87Exceptional
87Exceptional
85Exceptional
85Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$178.76
Change on the day-1.93%
52-week range$153.41–$212.71
Market capitalisation$277B—
Price / earnings (trailing)25.58
Shares traded on the day2.54M
Beta (volatility vs the S&P 500)0.21
Dividends per share (last 12 months)$3.23
Dividend yield (last 12 months)1.77%

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $156, high $208, latest $179. 4 reported quarters marked, 4 above and 0 below the recorded estimate. 1 other dated event marked. $208 $156 high $208 Feb 10, 2026 · Earnings results · reported above the recorded estimate · close $2061Apr 29, 2026 · Earnings results · reported above the recorded estimate · close $1852Jul 27, 2026 · Earnings results · reported above the recorded estimate · close $1693Oct 30, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $1874Oct 30, 2026 · Earnings results · reported above the recorded estimate · close $1875 Oct 17, 2025 Nov 18, 2026 · $179 $171Oct 17, 2025$165Oct 31, 2025$175Nov 14, 2025$184Nov 28, 2025$180Dec 12, 2025$181Dec 26, 2025$191Jan 9, 2026$178Jan 23, 2026$193Feb 6, 2026$204Feb 20, 2026$194Mar 6, 2026$184Mar 20, 2026$203Apr 2, 2026$205Apr 17, 2026$185May 1, 2026$182May 15, 2026$186May 29, 2026$179Jun 12, 2026$188Jun 26, 2026$172Jul 10, 2026$169Jul 24, 2026$161Aug 7, 2026$166Aug 21, 2026$163Sep 4, 2026$166Sep 18, 2026$157Oct 2, 2026$165Oct 16, 2026$187Oct 30, 2026$184Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate

Management outlook

  • R&D represented 23% of total revenue in the first 9 months, and we continue to expect it to be at the upper end of the low 20s percentage range for the full year.

    Aradhana Sarin · Statement from

  • As we indicated previously, we expect gross margin in the second half to be below the first half, reflecting the seasonal demand profile of lower-margin medicines such as FluMist and Beyfortus.

    Aradhana Sarin · Statement from

How to read these dates

A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

Read management statements

Other perspectives

Council score for AstraZeneca (AZN): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Strong
Financial Safety Neutral
Valuation Neutral
Growth Durability Strong
Momentum Strong

Legends Council

5 lenses, 5 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Moderate
Revenue Growth Neutral
Debt/Equity Weak
ROE Strong
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company less favourably than the MoonshotScore does: Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is AstraZeneca (AZN), and what does it report?

Short answer · as of

AstraZeneca is an integrated global biopharmaceutical company, not a development-stage biotech awaiting a flagship approval. It sells established prescription medicines through primary and specialty care channels while funding discovery, clinical development, manufacturing and commercialization across a broad geographic network.

The reporting mixes therapeutic-area totals with named medicine sales: oncology and rare disease appear alongside Tagrisso and Farxiga, while cardiovascular, renal and metabolic medicine revenue is also grouped as a franchise. Those lines describe the portfolio from different angles and should not be treated as mutually exclusive components.

2 · Latest results

What do the latest results show for AstraZeneca (AZN)?

Revenue edged higher in the latest reported period, and gross profit also advanced, but operating profit, net income and earnings per share retreated as research and commercial spending rose. Reported earnings exceeded expectations while revenue came in slightly below expectations, breaking the recent run of revenue outperformance without erasing the broader annual growth trend.

Management reiterated its constant-currency growth outlook and continues to direct an elevated share of revenue toward research spanning oncology technologies and the cardiovascular, renal and metabolic pipeline. It also expects product mix to pressure gross margin as seasonal demand shifts toward lower-margin FluMist and Beyfortus, making the revenue mix as important as the revenue direction.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$15.99B Sep 30, 2026
Latest quarter · R&D
$3.60B Sep 30, 2026
Latest quarter · SG&A
$5.26B Sep 30, 2026
Latest quarter · FMP standardized operating result
$4.32B Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$15.99B$3.60B$5.26B$4.32B
Jun 30, 2026$15.38B$4.05B$5.80B$3.16B
Mar 31, 2026$15.29B$3.49B$5.06B$4.25B
Dec 31, 2025$15.50B$3.86B$5.64B$2.98B
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$16.21B Oct 30, 2026
Latest report · revenue estimate
$16.00B Oct 30, 2026
Latest report · revenue vs estimate
Above estimate Oct 30, 2026
Latest report · EPS vs estimate
Above estimate Oct 30, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Oct 30, 2026$16.21B$16.00B$2.7900$2.6000
Jul 27, 2026$15.38B$15.44B$2.6300$2.5000
Apr 29, 2026$15.29B$14.93B$2.5800$2.5700
Feb 10, 2026$15.50B$15.44B$2.1200$2.0900
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$15.19B$2.53B$1.62 (diluted)
Q4 FY2025$15.50B$2.33B$1.48 (diluted)
Q1 FY2026$15.29B$3.08B$1.97 (diluted)
Q2 FY2026$15.38B$2.51B$1.59 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for AstraZeneca (AZN)?

Short answer

Cash and short-term investments were $8.15B at the Sep 30, 2026 balance-sheet date. Operating cash flow was $4.66B for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

Operating cash flow has remained positive throughout the displayed history despite substantial capital expenditure and rising research investment. Profitability screens remain healthy, but the latest cash balance declined from the preceding period and near-term liquidity ratios indicate that liquid current resources do not fully cover current obligations.

Debt materially exceeds cash and short-term investments, and it remains larger even when long-term investment holdings are included. AstraZeneca therefore needs its marketed portfolio to keep funding pipeline investment and capital needs; weaker sales from major franchises, heavier commercialization expense or the expected unfavorable product mix would reduce the room available for debt service and reinvestment.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$4.66B Sep 30, 2026
Previous quarter · operating cash flow
$2.89B Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026$4.66B−$666.87M
Jun 30, 2026$2.89B−$752.85M
Mar 31, 2026$3.36B−$1.54B
Dec 31, 2025$2.43B−$1.05B
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at AstraZeneca (AZN)?

Short answer · as of

The next earnings report is expected on Feb 9, 2027.

The upcoming report should be read through product mix rather than revenue alone. Watch whether overall sales maintain momentum, whether earnings growth holds as research and commercial costs rise, and whether the anticipated FluMist and Beyfortus mix change produces the gross-margin pressure management described.

Cash conversion is the financial cross-check: operating cash flow should remain sufficient after capital spending while cash, investments and debt stay in balance. Tagrisso, Farxiga, the broader oncology franchise and rare disease sales deserve particular attention because their scale makes them central to whether commercial growth can absorb sustained pipeline investment.

What management is planning

Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.

  1. As in prior years, we expect a sequential step-up in the fourth quarter versus third quarter in operating expenses.

    Aradhana Sarin ·

  2. We expect the other operating income in the second half of the year to be slightly higher than the first half.

    Aradhana Sarin ·

2 more statements are quoted under Upcoming events

5 · Peer comparison

How does AstraZeneca compare with its peers?

Short answer

AstraZeneca's score ranks tied for 3rd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

AstraZeneca combines the commercial reach of a global drug manufacturer with research spending more commonly associated with an aggressively expanding pipeline. Unlike a biotech whose value rests mainly on future approvals, AstraZeneca already draws substantial sales from oncology, cardiovascular, renal, metabolic and rare-disease medicines while developing new modalities through internal work and collaborations.

Oncology is the largest disclosed therapeutic grouping, but the business is not an oncology pure play: Farxiga, the wider cardiovascular, renal and metabolic franchise, and rare disease provide meaningful commercial breadth. That mix spreads demand across established medicines and treatment areas, while retaining exposure to the research cost and execution risk inherent in bringing new therapies to market.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eli Lilly and Company (LLY) Named competitor$1382.75 Nov 18, 2026$1.23T98 5-pillar Nov 18, 2026
Sanofi (SNY) Same industry, near in market value$47.12 Nov 18, 2026$113B87 5-pillar Nov 18, 2026
AstraZeneca (AZN) — this page$178.76$277B85
Bristol-Myers Squibb Company (BMY) Same industry, near in market value$59.56 Nov 18, 2026$122B85 5-pillar Nov 18, 2026
Amgen Inc. (AMGN) Same industry, near in market value$443.89 Nov 18, 2026$240B84 5-pillar Nov 18, 2026
Johnson & Johnson (JNJ) Named competitor$272.70 Nov 18, 2026$656B83 5-pillar Nov 18, 2026
AbbVie Inc. (ABBV) Named competitor$286.01 Nov 18, 2026$506B83 5-pillar Nov 18, 2026
Novartis AG (NVS) Named competitor$155.21 Nov 18, 2026$293B82 5-pillar Nov 18, 2026
GSK plc (GSK) Same industry, near in market value$48.58 Nov 18, 2026$97.4B77 5-pillar Nov 18, 2026
Gilead Sciences, Inc. (GILD) Same industry, near in market value$168.98 Nov 18, 2026$210B72 5-pillar Nov 18, 2026
Merck & Co., Inc. (MRK) Named competitor$137.78 Nov 18, 2026$340B69 5-pillar Nov 18, 2026
Pfizer Inc. (PFE) Same industry, near in market value$28.06 Nov 18, 2026$160B67 5-pillar Nov 18, 2026
Grifols, S.A. (GRFS) Same industry, near in market value$8.47 Nov 18, 2026$5.76B60 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$206.00 – $216.00
Consensus target
$211.00
Median target
$211.00

Consensus record · Captured .

Measured against a quoted price of $178.76 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 6, 2026

Transactions
7
Identified insiders
1
Purchases
1
Sales
0
Other transactions
6

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
51.0% Period end Sep 30, 2026
Previous quarter · ownership
52.0% Prior to period end Sep 30, 2026
Reporting holders
1,478 Period end Sep 30, 2026
Previous quarter · holders
1,529 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Investor Ab51,587,810
Vanguard Capital Management LLC45,656,840
Capital World Investors31,088,437
Wellington Management Group Llp30,837,503
Fmr LLC29,383,096

Tracked investors

Which of the 16 named investors we follow held AZN in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported AZN in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about AstraZeneca (AZN)?

Read these with our analysis →

AstraZeneca Healthcare Stock: Key Questions Answered

The last 3 questions are answered from this page's own dated data, not from the research.

How do Tagrisso and Farxiga fit into AstraZeneca’s reported revenue?

Tagrisso and Farxiga are named medicine sales presented alongside broader therapeutic-area totals. Adding every displayed line together would overstate revenue because the presentation describes overlapping portfolio views rather than independent segments.

Why can AstraZeneca’s gross margin weaken while revenue grows?

Management expects seasonal demand for lower-margin FluMist and Beyfortus to weigh on product mix. Revenue can therefore advance while the profit retained from each unit of sales declines.

Can AstraZeneca fund its pipeline from operating cash flow?

Operating cash flow has stayed positive across the displayed periods while research spending remained elevated, although capital expenditure absorbs a meaningful portion. The durability of that funding model depends on marketed medicines continuing to support pipeline and infrastructure investment.

Is AstraZeneca mainly an oncology company?

Oncology is its largest disclosed therapeutic grouping, led in part by Tagrisso, but AstraZeneca also has substantial cardiovascular, renal, metabolic and rare-disease businesses. Farxiga and the rare-disease portfolio make the company broader than an oncology pure play.

What is the AZN stock price today?

The last price recorded for AstraZeneca PLC (AZN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the AZN price target?

The analyst consensus price target for AstraZeneca PLC (AZN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Does AZN pay a dividend?

Yes. The dividend yield of AstraZeneca PLC (AZN) over the last 12 months, with its date, is listed under Price & valuation on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 83 figures on this page — 2 from SEC filings and earnings calls, 71 from Financial Modeling Prep (FMP), 4 with no recorded source, 5 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Cash, investments and debt
  • 1. What is AstraZeneca (AZN), and what does it report?: Business description; Sector / industry (provider taxonomy); Revenue by segment; Annual revenue and net result (USD millions)
  • 2. What do the latest results show for AstraZeneca (AZN)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for AstraZeneca (AZN)?: Operating cash flow by quarter (USD millions); Annual revenue and net result (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash against market value; Trailing twelve-month ratio set; Distress and quality screens; Revenue by segment; Management outlook — dated call excerpts
  • 4. What should you watch next at AstraZeneca (AZN)?: Next earnings report; Analyst revenue and earnings estimates (average); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and short-term investments over time (USD millions); Revenue by segment; Management outlook — dated call excerpts
  • 5. How does AstraZeneca compare with its peers?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Management outlook — dated call excerpts
  • FAQ: How do Tagrisso and Farxiga fit into AstraZeneca’s reported revenue?: Business description; Revenue by segment
  • FAQ: Why can AstraZeneca’s gross margin weaken while revenue grows?: Management outlook — dated call excerpts; Quarterly income statement (USD thousands)
  • FAQ: Can AstraZeneca fund its pipeline from operating cash flow?: Operating cash flow by quarter (USD millions); Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Management outlook — dated call excerpts
  • FAQ: Is AstraZeneca mainly an oncology company?: Business description; Revenue by segment
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold AZN

Funds in our ETF coverage that list AZN among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
Thornburg International Equity ETF (TXUE)3.36%